Ozempic: What It Actually Does, What Science Really Says
Ozempic: What It Actually Does, What Science Really Says
A real look at semaglutide, stripped of the hype and the panic.
Everyone has an opinion on Ozempic. Half your social media feed says it's a miracle. The other half is convinced it's dangerous. The actual clinical evidence sits somewhere less dramatic, and honestly more interesting, than either camp.
I want to walk you through what semaglutide actually does in your body, what the major trials show, and where the real unknowns still live. No cheerleading. No scaremongering.
What Ozempic Actually Is
Semaglutide, sold as Ozempic for type 2 diabetes and Wegovy for obesity, is a GLP-1 receptor agonist. That sounds complicated. It's not, really.
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases when you eat. It tells your pancreas to produce more insulin, tells your liver to stop dumping glucose, and signals your brain that you're full. Semaglutide mimics that hormone, just with a longer half-life. You inject it once a week and it keeps doing its thing.
The original Ozempic approval was for type 2 diabetes management. The weight loss applications came later, after trials showed the weight reduction was substantial enough to treat separately.
The Heart Health Evidence
This is where things get clinically meaningful. The SUSTAIN-6 trial, published in the New England Journal of Medicine, ran for 2 years across 3,297 patients. People taking semaglutide had a 26% lower rate of major cardiovascular events.
The SELECT trial in 2023 went further. It looked at 17,604 overweight adults without diabetes and found a 20% reduction in cardiovascular events with semaglutide 2.4mg over about 3.5 years. These weren't people on Ozempic for weight loss aesthetics. They had existing cardiovascular disease.
That cardiac protection signal is real. The mechanism isn't fully understood (reduced inflammation? better blood glucose control? the weight loss itself?), but the outcome data is solid.
What It Does to Blood Sugar
For type 2 diabetes, semaglutide works on 3 fronts: it boosts insulin when glucose is high, suppresses glucagon (the hormone that raises blood sugar), and slows how fast food leaves your stomach.
HbA1c, the 3-month average blood sugar marker, drops by roughly 1.5 to 1.8 percentage points on semaglutide. To put that in real terms: if your HbA1c is 8.5% (poorly controlled), you could get it down to around 6.7 to 7.0% (well-controlled territory) on this medication alone.
It also carries a low risk of hypoglycemia compared to older diabetes drugs like sulfonylureas. That's a genuinely good thing.
The Weight Loss Reality
The STEP 1 trial showed an average 15% body weight loss at 68 weeks with 2.4mg semaglutide. That's significant. It's more than most other weight loss medications have produced in trials.
But there's a caveat that doesn't get enough airtime: the weight comes back when you stop. The STEP 4 extension trial showed that people who discontinued semaglutide regained about two-thirds of the lost weight within a year.
This means semaglutide is, for many people, a lifelong medication if the goal is sustained weight control. That changes the risk-benefit calculation, especially over decades. We simply don't have 20-year safety data yet.
The Side Effects Worth Knowing
The most common ones are gastrointestinal: nausea, vomiting, diarrhea, constipation. In the STEP trials, around 44% of participants reported nausea. Most of it settled after the first 4 to 8 weeks, especially with the slow dose escalation protocol.
The rarer but more serious concerns:
Pancreatitis
GLP-1 drugs have carried a pancreatitis signal since the class first emerged. The absolute risk is low (probably around 0.1 to 0.2% per year), but it's real. If you develop severe upper abdominal pain that radiates to your back, stop the medication and get checked.
Thyroid C-cell Tumors
Rodent studies showed thyroid C-cell hyperplasia with GLP-1 agonists. This led to a black box warning. Human data so far hasn't shown a convincing signal, but semaglutide is contraindicated if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Muscle Loss
The weight loss includes some muscle mass loss, not just fat. Studies suggest roughly 25 to 39% of weight lost on semaglutide comes from lean tissue. Resistance training while on the medication partially counteracts this.
Semaglutide is contraindicated in pregnancy, personal or family history of medullary thyroid carcinoma, MEN2 syndrome, and severe gastroparesis. Always discuss your full medical history with your prescribing physician before starting.
The "Ozempic Face" Problem
This one's interesting. The rapid weight loss, especially from the face, can make people look gaunt or aged. Dermatologists have noted increased requests for facial filler and skin-tightening procedures from people on GLP-1 drugs. It's not a medical risk, but it's a cosmetic reality worth knowing about going in, particularly with aggressive dose escalation.
What We Don't Know Yet
Long-term renal effects beyond 5 years. The impact on bone density with sustained use. Whether the cardiovascular benefits persist in people without pre-existing disease. How it interacts with pregnancy later in life after prolonged use. These aren't reasons to avoid the medication, they're honest gaps in what the literature has had time to show us.
Semaglutide has been around since 2017. Seven years of data in millions of patients is more than most drugs get before mass prescribing, but it's not 30 years either.
The Bottom Line
Semaglutide is a genuinely effective medication for type 2 diabetes and obesity. The cardiovascular outcome data is strong. The side effect profile is manageable for most people. The metabolic improvements are real.
The parts that deserve more honest conversation: it's probably a long-term commitment, the muscle loss issue needs more attention, and we're still accumulating data on decade-plus use.
It's not a miracle. It's a good drug with a clear evidence base, used thoughtfully in the right patients.
"The best medication is the one you need, at the right dose, for the right reason, with your eyes open to the trade-offs."
Comments
Post a Comment